

**LINCOMED 100- lincomycin injection**  
**Bimeda Inc., Division of Cross Vetpharm Group**

-----  
ANADA 200-368, Approved by FDA

**LincoMed<sup>®</sup> 100**

**lincomycin injection, USP**

**For Intramuscular Use in Swine Only**

LincoMed<sup>®</sup> 100 contains lincomycin hydrochloride, an antibiotic produced by *Streptomyces lincolnensis* var. *lincolnensis* which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid.

**INDICATIONS FOR SWINE:**

LincoMed<sup>®</sup> 100 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, *Erysipelothrix* and *Mycoplasma spp.*

It is also indicated for the treatment of mycoplasma pneumonia.

**CONTRAINDICATIONS:**

As with all drugs, use of LincoMed<sup>®</sup> 100 is contraindicated in animals previously found to be hypersensitive to the drug.

**Residue Warning:** Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.

**Human Warnings:** Not for use in human. Keep out of reach of children.

**CAUTION:**

If no improvement is noted within 48 hours, consult a veterinarian.

**ADVERSE REACTIONS:**

The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur. Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.

**DOSAGE AND ADMINISTRATION:**

For arthritis or mycoplasma pneumonia - 5 mg per pound of body weight intramuscularly once daily for three to seven days as needed. One mL per 20 lb body weight will provide 5 mg/lb.

For optimal results, initiate treatment as soon as possible. As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

**Each mL contains:**

Lincomycin hydrochloride equivalent to lincomycin 100 mg; also benzyl alcohol 9.45 mg added as a preservative.

**HOW SUPPLIED:**

LincoMed<sup>®</sup> is available in two concentrations: 100 mg/mL and 300 mg/mL.

100mg/mL: Supplied in 100 mL multiple dose vial.

300 mg/mL: *For use in swine weighing 300 pounds or more.* Supplied in 100 mL multiple dose vial.

**STORE AT 20°C - 25°C (68°F - 77°F).**

**KEEP FROM FREEZING**


For Intramuscular Use in Swine

**DOSAGE:** Usual daily dose for arthritis or mycoplasma pneumonia - 5 mg per pound of body weight (1 mL per each 20 pounds of body weight) intramuscularly for three to seven days. See package insert for complete product information.

**Residue Warning:** Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.

**Human Warnings:** Not for use in humans. Keep out of reach of children.

**STORE AT 20°C - 25°C (68°F - 77°F).  
KEEP FROM FREEZING.**



**Contains per mL:** Lincomycin hydrochloride equivalent to lincomycin 100 mg; also benzyl alcohol 9.45 mg added as a preservative.

**INDICATIONS:** Indicated for the treatment of arthritis caused by susceptible organisms and for mycoplasma pneumonia.

LincoMed® is a registered trademark of Bimeda, Inc.

Manufactured by:  
Bimeda-MTC Animal Health Inc.  
Cambridge, ON Canada  
N3C 2W4

Manufactured for:  
Bimeda, Inc.  
Le Sueur, MN 56058  
www.bimeda.com

Product No. 1LIND19 8LIND01C Rev. 03/14



## LINCOMED 100

lincomycin injection

### Product Information

<b>Product Type</b>	OTC ANIMAL DRUG	<b>Item Code (Source)</b>	NDC:61133-6000
<b>Route of Administration</b>	INTRAMUSCULAR		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LINCOMYCIN HYDROCHLORIDE (UNII: M6T05Z2B68) (LINCOMYCIN - UNII:BOD072YW0F)	LINCOMYCIN	100 mg in 1 mL

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:61133-6000-1	100 mL in 1 VIAL, MULTI-DOSE		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200368	08/02/2006	

**Labeler** - Bimeda Inc., Division of Cross Vetpharm Group (060492923)

**Registrant** - Bimeda Inc., Division of Cross Vetpharm Group (060492923)

**Establishment**

Name	Address	ID/FEI	Business Operations
Bimeda-MTC Animal Health, Division of Cross Vetpharm Group		256232216	manufacture

### Establishment

Name	Address	ID/FEI	Business Operations
Xinyu Pharmaceutical Co., Ltd.		654258862	api manufacture

### Establishment

Name	Address	ID/FEI	Business Operations
JIANGXI GUOYAO PHARMACEUTICAL, LLC., CO.		420560294	api manufacture

Revised: 10/2016

Bimeda Inc., Division of Cross Vetpharm Group